Wedbush Has Bullish Outlook for APLS FY2025 Earnings

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Wedbush boosted their FY2025 EPS estimates for shares of Apellis Pharmaceuticals in a report issued on Tuesday, July 15th. Wedbush analyst L. Chico now anticipates that the company will post earnings per share of ($0.16) for the year, up from their previous forecast of ($0.22). The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.70) per share. Wedbush also issued estimates for Apellis Pharmaceuticals’ Q4 2025 earnings at ($0.52) EPS.

Several other equities analysts have also weighed in on the company. Morgan Stanley lifted their price objective on Apellis Pharmaceuticals from $25.00 to $26.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 2nd. Scotiabank reduced their price objective on Apellis Pharmaceuticals from $28.00 to $20.00 and set a “sector perform” rating on the stock in a research note on Thursday, May 8th. Raymond James Financial lowered Apellis Pharmaceuticals from a “strong-buy” rating to an “outperform” rating and reduced their price objective for the company from $75.00 to $52.00 in a research note on Friday, May 9th. Needham & Company LLC reduced their price objective on Apellis Pharmaceuticals from $40.00 to $29.00 and set a “buy” rating on the stock in a research note on Wednesday, May 7th. Finally, Robert W. Baird reduced their price objective on Apellis Pharmaceuticals from $55.00 to $47.00 and set an “outperform” rating on the stock in a research note on Thursday, May 8th. Nine analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $39.84.

Apellis Pharmaceuticals Stock Performance

NASDAQ APLS opened at $20.04 on Thursday. The firm has a market capitalization of $2.52 billion, a P/E ratio of -11.20 and a beta of 0.67. Apellis Pharmaceuticals has a 1-year low of $16.10 and a 1-year high of $41.94. The company has a debt-to-equity ratio of 2.76, a current ratio of 4.08 and a quick ratio of 3.62. The business’s 50-day simple moving average is $18.19 and its 200-day simple moving average is $22.73.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.38). The business had revenue of $149.90 million during the quarter, compared to analysts’ expectations of $197.61 million. Apellis Pharmaceuticals had a negative net margin of 28.83% and a negative return on equity of 99.19%. The firm’s quarterly revenue was down 3.2% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.54) EPS.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the stock. Wealth Enhancement Advisory Services LLC boosted its position in Apellis Pharmaceuticals by 43.5% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 100,666 shares of the company’s stock worth $1,838,000 after acquiring an additional 30,507 shares during the period. Pallas Capital Advisors LLC boosted its position in Apellis Pharmaceuticals by 29.0% during the 2nd quarter. Pallas Capital Advisors LLC now owns 54,849 shares of the company’s stock worth $949,000 after acquiring an additional 12,315 shares during the period. Parallel Advisors LLC boosted its position in Apellis Pharmaceuticals by 80.0% during the 2nd quarter. Parallel Advisors LLC now owns 1,924 shares of the company’s stock worth $33,000 after acquiring an additional 855 shares during the period. Goldman Sachs Group Inc. boosted its position in Apellis Pharmaceuticals by 26.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 307,709 shares of the company’s stock worth $6,730,000 after acquiring an additional 64,742 shares during the period. Finally, Voya Investment Management LLC boosted its position in Apellis Pharmaceuticals by 1.8% during the 1st quarter. Voya Investment Management LLC now owns 125,401 shares of the company’s stock worth $2,743,000 after acquiring an additional 2,250 shares during the period. 96.29% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, General Counsel David O. Watson sold 5,000 shares of the company’s stock in a transaction on Monday, June 16th. The stock was sold at an average price of $18.77, for a total transaction of $93,850.00. Following the completion of the transaction, the general counsel directly owned 133,730 shares in the company, valued at $2,510,112.10. This represents a 3.60% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Cedric Francois sold 1,900 shares of the company’s stock in a transaction on Tuesday, July 15th. The stock was sold at an average price of $20.09, for a total value of $38,171.00. Following the transaction, the chief executive officer owned 342,333 shares of the company’s stock, valued at approximately $6,877,469.97. The trade was a 0.55% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 144,365 shares of company stock valued at $2,907,439 over the last quarter. Company insiders own 6.50% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).